The flotation was priced at $7 per share, $0.50 below the estimated price range.
Israeli biotech company Rosetta Genomics has completed its IPO on Nasdaq, raising $26.3 million. The company issued 3.75 million shares at $7 each, $0.50 less than the lower end of the price range. The company’s value in the flotation was $79 million. CE Unterberg Towbin, LLC acted as the lead manager and the sole bookrunner for the offering with Oppenheimer & Co. Inc. as co-manager.
Rosetta Genomics has developed a unique computerized algorithm for researching microRNA gene sequences. The company will be listed for trading on Nasdaq under the ticker ROSG, and in honor of the occasion it has been selected to ring the bell at the end of today’s session.
Published by Globes [online], Israel business news - www.globes.co.il - on February 27, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007